Prescription drug costs are one of the more unpredictable line items in a retiree’s monthly budget, since the amount owed at the pharmacy depends on where a person stands relative to their plan’s deductible and annual out-of-pocket limit. For 2027, the two numbers that anchor that math are both set to rise: the standard Part D deductible is climbing to $700, and the annual cap on what a beneficiary pays out of pocket for covered drugs is rising to $2,400. Unlike some of the other Medicare figures still floating as early estimates for next year, these two numbers are no longer projections; the federal government has already finalized them.
The 2027 Part D Deductible and Cap, Already Finalized
Unlike the Part B premium, which remains a projection until the Centers for Medicare & Medicaid Services makes its fall announcement, the core 2027 Part D benefit numbers are already locked in. That distinction matters for anyone trying to budget ahead: a beneficiary can plan around the deductible and out-of-pocket cap with real confidence, while treating any Part B or IRMAA figure for 2027 as a working estimate until CMS confirms it later this year. The Centers for Medicare & Medicaid Services confirmed the 2027 Part D deductible at $700 in an April 6, 2026 announcement tied to its Retiree Drug Subsidy program, a $85 increase from the $615 deductible in 2026. The same finalized parameters set the 2027 out-of-pocket maximum at $2,400, a $300 increase over the $2,100 cap that applies in 2026.
Once a beneficiary’s total drug spending for the year, including certain payments made on their behalf, reaches that $2,400 cap, covered prescriptions cost nothing for the rest of the year, a threshold confirmed in the same CMS Retiree Drug Subsidy announcement. That annual cap is a relatively recent feature of Part D, created by the Inflation Reduction Act, and 2027 will be its third full year in effect after replacing the older system in which catastrophic coverage still left beneficiaries paying 5 percent coinsurance indefinitely.
Free retirement updates: Enrollment and claim windows come and go, and missing one can cost you real money. The free Retirement Shield newsletter keeps you ahead of the deadlines that matter. Sign up free.
How the Deductible Increase Compares With Recent Years
The jump to $700 is steeper than what beneficiaries saw heading into 2026, when the deductible rose a comparatively modest $25, from $590 to $615. A $85 increase for 2027 represents growth of nearly 14 percent in a single year, according to Kiplinger’s review of the Medicare Trustees Report projections for the coming decade, which also tracks the Part D base premium rising to $41.33 in 2027, up from $38.99 in 2026. That base premium isn’t what most beneficiaries actually pay, since individual Part D plan premiums vary by insurer and region, but it is the standardized figure the Social Security Administration uses to calculate late-enrollment penalties and income-related surcharges. A separate premium stabilization provision in the Inflation Reduction Act caps how much a plan sponsor’s base beneficiary premium can grow year over year through 2029, which is part of why the base premium’s projected 6 percent rise for 2027 is smaller in percentage terms than the deductible’s nearly 14 percent jump.
Beyond 2027, the same projections show the deductible and out-of-pocket cap continuing to climb through the next decade, with the out-of-pocket cap projected to reach several hundred dollars higher by the early 2030s as prescription drug spending, particularly for costly specialty and GLP-1 medications, continues to outpace general inflation. Part D as a whole has grown faster than Part B in recent years, driven partly by an increase in the use of high-cost injectable and specialty drugs, a trend the Trustees expect to keep pressuring both deductibles and premiums well past 2027.
Why the Out-of-Pocket Cap Matters More Than the Deductible Alone
For a beneficiary managing a single inexpensive generic prescription, the deductible increase may barely register. For someone managing several brand-name medications or a costly specialty drug, the annual out-of-pocket cap is the number that actually protects the household budget, since it puts a hard ceiling on total drug spending for the year regardless of how expensive the underlying medications are. Before the cap existed, a beneficiary with high drug costs could face thousands of dollars in coinsurance with no yearly limit. The shift to a hard dollar cap, phased in over the past two years, replaced a “catastrophic coverage” phase that sounded protective on paper but still left beneficiaries paying 5 percent of every prescription’s cost indefinitely once they reached it, with no ceiling on the total.
Beneficiaries who expect to hit the cap early in the year, because of an expensive ongoing prescription, may also want to look into the Medicare Prescription Payment Plan, a separate option that lets a beneficiary spread out-of-pocket drug costs into monthly installments across the calendar year rather than paying a large amount in January and February. It doesn’t lower the $2,400 cap itself, but it changes when the money is due, which can matter as much as the total for a household on a fixed monthly income. A beneficiary interested in that option needs to opt in through their Part D plan, since it isn’t automatic, and enrolling doesn’t change the total amount owed for the year, only the timing of the payments.
This article was produced with AI assistance and reviewed by The Financial Wire editorial team.
More Financial Reading
- The ideal retirement withdrawal rate so your savings actually last
- Adding someone to your bank account: tax traps and smart moves
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
